- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
Tonix Pharmaceuticals Prices $15,000,000 Public Offering
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
